key: cord-0867237-t6z3aa0p authors: Gupta, Subash; Sudhindran, S.; Saraf, Neeraj; Vijai, Anand; Swaminathan, Subramaniam; Panackel, Charles; Mehta, Naimish N.; Varghese, Joy; Singh, Shweta; Reddy, Mettu Srinivas; Viswanathan, M.S.; Bhangui, Prashant; Mohanka, Ravi; Asthana, Sonal; Rohatgi, Sanjeev title: Liver Transplant Society of India Guidelines for Liver Transplant during COVID-19 times date: 2021-08-20 journal: J Clin Exp Hepatol DOI: 10.1016/j.jceh.2021.08.012 sha: 7a5e2296011fcc950eca9a77fe2658789ca35eef doc_id: 867237 cord_uid: t6z3aa0p COVID-19 pandemic has affected liver transplantation in many ways. There is risk of infection to the transplant recipients; and COVID-19 is associated with significant risk of mortality in patients on wait list. The Liver Transplant Society of India has prepared guidelines regarding selection of adult and pediatric patients for liver transplantation, transplant for acute liver failure, use of deceased donor organs, transplant techniques and minimally invasive donor hepatectomy, pre and post-surgery testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related coronavirus disease 2019 in donors and recipients, role of COVID-19 antibody testing, shifting of recipients from COVID-19 to non-COVID-19 areas after recovery, isolation policy of team members exposed to COVID-19 patients, drug therapy of proven or suspected COVID-19 infection early post-transplant, care of SARS-CoV-2 positive donors and recipients and a separate COVID-19 consent for surgery. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) related coronavirus disease-2019 (COVID- 19) pandemic has had profound effects on the health system and every country in the world has struggled to overcome its ill consequences. At many hospitals, routine activity has declined markedly so that the care of COVID-19 patients can happen. In the year 2020, there was so much panic that even cadaveric donations were proscribed by National Organ and Tissue Transplant Organization (NOTTO). 1 The LTSI formulated guidelines for transplants during the first wave of COVID-19 in India 2 which led to gradual resumption of liver transplant services. Subsequently, as the second surge happened rather unexpectedly consequent on early easing of restrictions, development of mutants and COVID-19 fatigue causing risky behaviour, healthcare resources have been severely constrained leading to shortage of oxygen, intensive care beds and ventilators. 3 This second wave has driven home the point that this pandemic will not end overnight. 4 The Society feels that liver transplant activity by virtue of it being lifesaving must continue during this period. At the same time, attempt must be made to reduce the risk of infection in donors, not to compromise outcomes in recipients and to protect the team who provide care to these recipients. These guidelines are meant for management of liver diseases in COVID-19 period (and not just for COVID-19 peaks). The Executive met on several occasions to formulate these guidelines for Liver Transplant Activity in the COVID-19 Era. A questionnaire was framed which was circulated in the Executive and to the high-volume liver transplant centres, opinion was taken from experts treating COVID-19 patients, a review of published guidelines from around the world was carried out and agreement was reached on most of the clinical issues. Where there was no 1. Liver transplant indications for adult and paediatric patients. LTSI acknowledges that LT in COVID-19 times may be a difficult endeavour and centres must ensure recipient and donor safety. At times of local surges, transplant activity may be reduced so as not to overwhelm hospital resources. However, as there is no alternative to LT, activity must continue keeping in mind the anticipated mortality based on the CTP and MELD score. A rough guide to urgency can be decided based on Child and MELD scores. On the other hand, if the potential donor tests positive, donation should not proceed. One must also keep in mind that the donor may have been similarly exposed and the team must satisfy themselves that the negative PCR test is not a consequence of testing too early after exposure. The operation should be carried out with full personal protective equipment (PPE) cover, particularly at the time of induction. The team should don standard full PPE, apart from the lead surgeon and his first assistant as it may not be possible for them to wear magnifying loupes with PPE. However, waterproof gown, plastic apron, caps, masks, shoe covers, and glasses will suffice. The Hospital should designate an OT/OTs for COVID-19 cases as this may be necessary even for non-transplant cases which require urgent surgery. The use of organs from deceased donors without COVID-19 infection should proceed as usual. Prior to donation, a negative PCR test such as CBNAT would be mandatory. No recommendation can be made regarding use of livers from donors with adverse event following vaccination in absence of large size data. If the potential donor has had COVID-19 infection in the past, and a 3-week gap from the time of testing is there, liver donation can proceed as there is evidence that a positive test at this stage does not imply risk of transmission. 7 However, if the positive PCR test is more than 3 months old, a new test should be done. 8 The group acknowledged that there has been no reported case of donor to patient transmission of COVID-19 infection either from blood transfusion 9 or from liver donation, but it still felt strongly that cadaveric organs from a recently tested positive donor should be rejected to protect the huge numbers of personnel involved in organ retrieval. The group also recommended that Non-Heart Beating donors or machine perfusion of marginal donors should be suspended till the Hospital's positivity rate is less than 5%. 10 3. Minimally Invasive donor procedures and other transplant protocols At the start of the pandemic, fear about aerosol generation and spread of COVID-19 infection led to the initial recommendation that they should not be done. However, there has been sufficient evidence to suggest that this does not happen. 11 We suggest that use of minimally invasive procedures can be done as usual. Use of blood and blood products should be minimised as Blood Banks have The donors should also be considered for vaccination 3 weeks prior to planned donation. Following recovery from the transplant operation, vaccination should be carried out after 3 to 6 months. 14 LTSI recommended that antibody testing in donors and recipient was of no clinical value as antibodies may wane after infection or vaccination. All recipients and donors should be tested for active COVID-19 infection using an RT-PCR based testing methodology not less than 72 hours before the procedure to facilitate the arrangement of blood and blood products and reduce the pressure on laboratories performing the analysis. After negative COVID-19 testing, recipient and donor must follow strict isolation protocols. Some hospitals may have local protocols such as 2 negative tests before transplant and they may be adhered to in keeping with Institutional practice. If the recipient has tested positive and remained asymptomatic for 3 weeks, repeat testing would not be needed as RT-PCR tests may remain positive for extended periods even in patients with no viable viral particles. 7 The second surge has seen many young individuals developing life-threatening pneumonia and LTSI recommends that donors who have developed moderate or severe disease should be rejected even if they recover from their illness as longterm risks of lung fibrosis and risk of thromboembolism is not known. Donors who have had an asymptomatic or mild illness should ideally wait 7 weeks prior to donation. This is based on evidence from non-transplant studies which have reported that the peri-operative risk for patients undergoing surgery after a COVID-19 infection returns to baseline after 7 weeks. 15 The current guidelines from ICMR are that if the person is asymptomatic and recovered from transplant, they can be discharged without further testing. 18 Although, limited data shows that transplant recipients may have prolonged viral shedding, 19 LTSI suggests to follow ICMR guidelines in absence of high-quality data. In case where they still need transplant related care, but have recovered from COVID-19 infection, they can be shifted to the Transplant area once the RT PCR is negative. If according to local protocols, such as in the State of Kerala, rapid antigen testing is being used for decision making, it should be done at 10 days and repeated after another 7 days before the recipient can be shifted to a Non COVID-19 area. 20 10. Isolation policy of team members exposed to COVID-19 patients LTSI encourages that all team members of a liver transplant program should be fully vaccinated on priority. The team members who have completed their vaccination schedule and are asymptomatic need not undergo testing following low risk exposure. Care must be taken by non-vaccinated team members that they are not exposed without protection. All patients in the pandemic should be regarded as potentially Once recovery is happening, one must be alert to the possibility of rejection with Immune Reconstitution Syndrome. 23 Units which run on low tacrolimus levels combined with antimetabolites such as mycophenolate mofetil should continue to do so with the intention of keeping the level of immunosuppression low. 24 Limited data showed that use of mycophenolate at baseline may be associated with severe disease. 25 1. Vaccination must be encouraged to all transplant recipients. 2. If they need care, a member of ID team should be contacted and ensure that they are looked after. 3. Immunosuppressive medication may be adjusted if they have not been adjusted for a long time. If they are a year out after transplant, antimetabolites can be stopped. 4 . The use of monoclonal antibody should be considered and administered if eligible. 22 5. Treatment of blood pressure and diabetes should be advised. Patients and family should be made aware about the risks of carrying out a major surgical procedure during the pandemic. There exists a definite risk of contracting COVID-19 from the health personnel during hospital admission. The risk if any, of performing major surgery on those who have recovered from mild COVID-19 disease or were asymptomatic, but COVID-19 test positive in the past is currently not known. Nevertheless, a small but finite risk of major complications and even mortality cannot be ruled out. It is particularly important for donors to be cognizant of this possibility. J o u r n a l P r e -p r o o f RT-PCR for donors and recipients prior to surgery Policy for donor and recipient testing following surgery 10. Shifting of Recipients from COVID-19 to non-COVID-19 areas after recovery of recipients who develop COVID-19 infection during follow up 16. Separate COVID-19 consent References: 1 Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI) COVID-19 vaccines: the pandemic will not end overnight Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3 Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose Repeat SARS-CoV-2 testing after recovery. Is a pretransplant PCR necessary? Duration of isolation and precautions for adults with COVID-19 COVID-19 transmission and blood transfusion: A case report What Is the Appropriate Use of Laparoscopy over Open Procedures in the Current COVID-19 Climate? Blood Bank Officer, Max Saket Super Specialty Hospital Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19 EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study SARS-CoV-2 Viral Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines. Front Med (Lausanne) Tacrolimusazithromycin interaction in a recipient of allogeneic bone marrow transplantation Real-World Effectiveness and Tolerability of Monoclonal Antibodies for Ambulatory Patients with Early COVID-19. medRxiv Cryptococcal Collaborative Transplant Study Group. Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation Queen Elizabeth Hospital Birmingham COVID-19 airway team. Safety and 30-day outcomes of tracheostomy for COVID-19: a prospective observational cohort study Funding: none J o u r n a l P r e -p r o o f